Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis

Ying Yang; Dong Wang; Lei Cui; Hong-Hao Ma; Li Zhang; Hong-Yun Lian; Qing Zhang; Xiao-Xi Zhao; Li-Ping Zhang; Yun-Ze Zhao; Na Li; Tian-You Wang; Zhi-Gang Li; Rui Zhang

doi:10.4143/crt.2020.769

Articles

Page Path: HOME > Cancer Res Treat > Volume 53(1); 2021 > Article

Original Article Pediatric cancer Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAF^V600E-Mutated Langerhans Cell Histiocytosis: Ying Yang¹, Dong Wang¹, Lei Cui², Hong-Hao Ma¹, Li Zhang¹, Hong-Yun Lian¹, Qing Zhang², Xiao-Xi Zhao¹, Li-Ping Zhang¹, Yun-Ze Zhao¹, Na Li², Tian-You Wang¹, Zhi-Gang Li², Rui Zhang¹; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2021;53(1):261-269.
DOI: https://doi.org/10.4143/crt.2020.769
Published online: September 15, 2020

¹Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics, Capital Medical University; Key Laboratory of Major Diseases in Children, Ministry of Education; Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

²Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

Correspondence: Rui Zhang, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key, Discipline of Pediatrics, Capital Medical University, Key Laboratory of Major Diseases in Children, Ministry of Education, Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China,
Tel: 86-13691156162, Fax: 86-10-59718600, E-mail: ruizh1973@126.com

Co-correspondence: Tian-You Wang, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key, Discipline of Pediatrics, Capital Medical University, Key Laboratory of Major Diseases in Children, Ministry of Education; Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China,
Tel: 86-13331119559, Fax: 86-10-59718600, E-mail: wangtianyou@bch.com.cn

Co-correspondence: Zhi-Gang Li, Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China,
Tel: 86-13370115085, Fax: 86-10-59718600, E-mail: ericlzg70@hotmail.com

* Ying Yang and Dong Wang contributed equally to this work.

• Received: August 2, 2020 • Accepted: September 14, 2020

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

34,805 Views
233 Download
19 Web of Science
24 Crossref
23 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
We sought to investigate the effectiveness and safety of dabrafenib in children with BRAF^V600E-mutated Langerhans cell histiocytosis (LCH).
Materials and Methods
A retrospective analysis was performed on 20 children with BRAF^V600E-mutated LCH who were treated with dabrafenib.
Results
The median age at which the patients started taking dabrafenib was 2.3 years old (range, 0.6 to 6.5 years). The ratio of boys to girls was 2.3:1. The median follow-up time was 30.8 months (range, 18.9 to 43.6 months). There were 14 patients (70%) in the risk organ (RO)⁺ group and six patients (30%) in the RO⁻ group. All patients were initially treated with traditional chemotherapy and then shifted to targeted therapy due to poor control of LCH or intolerance to chemotherapy. The overall objective response rate and the overall disease control rate were 65% and 75%, respectively. During treatment, circulating levels of cell-free BRAF^V600E (cfBRAF^V600E) became negative in 60% of the patients within a median period of 3.0 months (range, 1.0 to 9.0 months). Grade 2 or 3 adverse effects occurred in five patients.
Conclusion
Some children with BRAF^V600E-mutated LCH may benefit from monotherapy with dabrafenib, especially high-risk patients with concomitant hemophagocytic lymphohistiocytosis and intolerance to chemotherapy. The safety of dabrafenib is notable. A prospective study with a larger sample size is required to determine the optimal dosage and treatment duration.
Key words: Langerhans cell histiocytosis, BRAF^V600E, Dabrafenib, Children

Introduction

Langerhans cell histiocytosis (LCH) is a rare disease characterized by the proliferation of specific dendritic cells arising from myeloid progenitor cells and is currently considered a clonal disease [1]. LCH presents with a spectrum of clinical manifestations [2]. Low-risk children are affected in only a single organ or system, with a certain degree of self-limitation, and first-line chemotherapy is effective. High-risk patients are often under 3 years old and frequently have multiple organs or systems involved, especially the liver, spleen, or hematologic system. Thus, the risk of treatment-related death or disease progression is higher in the high-risk group than in the low-risk group [3,4].

BRAF kinase, which is encoded by the BRAF gene, plays a significant role in the RAS–mitogen-activated protein kinase (MAPK) signaling pathway. It was reported that the oncogenic BRAF^V600E mutation was identified in 35 of 61 LCH specimens (57%) and in up to 87.8% of children with multisystem- and risk-organ-involved LCH [4,5]. This mutation can drive constitutive ERK activation and lead to impaired migration and apoptosis in pathological LCH cells, which gives rise to LCH [1,6].

Dabrafenib is a reversible, ATP-competitive, selective BRAF kinase inhibitor [7] with a low incidence of adverse effects [8,9]. The role of dabrafenib in the treatment of BRAF^V600E-mutated LCH has been tested in a clinical trial (NCT01677741). The most common adverse events of dabrafenib are skin-related toxic effects (including maculopapular rash, skin pain and severe events including squamous cell carcinoma and keratocanthoma), fever, fatigue, arthralgia, etc. [10].

This study was designed to analyze the effectiveness and safety of dabrafenib in the treatment of 20 children with BRAF^V600E-mutated LCH who were cared for at our center.

Materials and Methods

1. Patients

From November 1, 2016, to November 30, 2018, 20 children (≤ 18 years old) with LCH who fulfilled all of the following criteria were enrolled in this study: (1) diagnosed with LCH according to clinical features, positive staining of CD1a and/or Langerin (CD207) of biopsy tissue; (2) BRAF^V600E could be detected in the peripheral blood or affected tissue at the onset of the disease; (3) chemotherapy could not be tolerated due to serious condition or severe chemotherapy-related adverse effects, or the disease continued to progress after chemotherapy, or the pituitary lesion was not improved after chemotherapy; and (4) no other BRAF kinase inhibitors had been used previously. In addition, Eastern Cooperative Oncology Group performance status 0–2 was a key inclusion criterion. All patients were followed until June 1, 2020.

2. Patient stratification

According to the involvement of risk organs, patients were divided into a risk organ-involved group (RO⁺ or high-risk group) or a risk organ-noninvolved group (RO⁻ or low-risk group). According to the cfBRAF^V600E level at the end of targeted therapy, patients were divided into a negative mutation group or a positive mutation group.

3. Therapeutic regimen

All patients were treated with chemotherapy according to the same protocol modified from LCH-III (without high-dose methotrexate) and HS-LCH salvage treatment after diagnosis, including first-line (vindesine+prednisone) and second-line treatment (cytarabine+vindesine+dexamethasone+/−cladribine). The details of the treatment elements are shown in S1 Table.

Targeted therapy with dabrafenib was initiated after the discontinuation of first-line or second-line treatment due to disease progression or intolerance to chemotherapy. For some patients not complicated by hemophagocytic lymphohistiocytosis (HLH), the disease was not severe enough, so dabrafenib was usually chosen after evaluation, which was performed one week after the discontinuation of chemotherapy. Patients with HLH were always in critical condition. Thus, if there was no improvement observed after chemotherapy, the patients underwent targeted therapy as soon as possible.

The dosage of dabrafenib was 2 mg/kg according to dose escalation and dose limiting toxicity evaluation in a phase I/II study on dabrafenib in children with refractory/resistant BRAF^V600E solid tumors [11], and for the treatment of pediatric BRAF^V600E mutated high-grade gliomas [12], dabrafenib was administered orally once every 12 hours. The general duration of the course of dabrafenib treatment was 6 months to 1 year, adjusted according to disease assessment and patient tolerance to the drug. The condition and adverse effects were evaluated after 1 month, 3 months, and every 3 months thereafter. After targeted therapy was completed, maintenance chemotherapy was given (6-mercaptopurine+ vindesine+prednisone). This regimen has been registered as a clinical trial (ChiCTR2000032844).

4. Determination of BRAF^V600E in tissue and plasma

The BRAF^V600E mutation was initially detected in tissue biopsies from 14 patients. Genomic DNA was extracted from 10×5 μm unstained sections of formalin-fixed paraffin-embedded (FFPE) tissue using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany). The presence of the BRAF^V600E mutation was then determined using a droplet digital polymerase chain reaction (ddPCR) assay with a QX200 Droplet Digital PCR system (Bio-Rad, Hercules, CA). FFPE tissues could not be obtained from the other six patients because no remaining tissue sample could be used for BRAF^V600E detection.

Plasma cell-free DNA from all 20 patients was isolated using the QIAamp Circulating Nucleic Acid Kit (Qiagen). Detection of cfBRAF^V600E was performed by ddPCR assay with a lower limit of detection of 0.04% and a lower limit of quantitation of 0.1%. The patient with cfBRAF^V600E level lower than 0.04% was regarded as negative accordingly. The laboratory has been certificated by Beijing Municipal Health and Family Planning Commission as Clinical Gene Amplification Test Laboratory, which is equivalent to Clinical Laboratory Improvement Amendments (CLIA)–approved laboratory.

5. Evaluation of the disease state and treatment response

The disease state and treatment response of the patients were evaluated according to the Histiocyte Society Evaluation and Treatment Guidelines published in 2009 [13,14]. Briefly, the disease states included nonactive disease (NAD) and active disease (AD). The treatment response was categorized as complete resolution (NAD), regression (AD-Better), mixed (AD-Mixed), stable (AD-Stable), and progression (AD-Worse).

For assessment of disease states, imaging modalities including radiography, ultrasound, computed tomography, and magnetic resonance imaging were used. Positron emission tomography computed tomography was used only in cases of inconclusive results from other imaging modalities.

The objective response rate (ORR) was defined as the percentage of patients with AD-Better among all patients, and the disease control rate (DCR) was defined as the percentage of patients with AD-Better and AD-Stable among all patients. Adverse effects were followed from the beginning of dabrafenib treatment through the last contact with the patients and were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, ver. 5.0 [15].

6. Statistical analysis

Statistical analysis was performed by using IBM SPSS ver. 24.0 software (IBM Corp., Armonk, NY). The count data were expressed by the number of cases or percentages, and Fisher exact test was used for the categorical variables. The measurement data with a normal distribution are expressed as the mean±standard deviation, while the measurement data with a nonnormal distribution are expressed as the median (minimum–maximum). For continuous variables, data were analyzed using the t test and Mann-Whitney U test, depending on the data distribution. Survival curves were estimated using the Kaplan-Meier method, and the log-rank test was used to estimate the differences among the groups. A p-value of < 0.05 was considered statistically significant.

Results

1. General information of the patients

The median ages of disease onset and initiation of dabrafenib were 1 year (range, 0.1 to 5.1 years) and 2.3 years (range, 0.6 to 6.5 years), respectively. The ratio of boys to girls was 2.3:1 (Table 1). The median follow-up time was 30.8 months (range, 18.9 to 43.6 months).

There were 14 patients (70%) in the RO⁺ group and six patients (30%) in the RO⁻ group. Four patients with disease states of AD-Stable or AD-Worse were treated with dabrafenib because of intolerance to chemotherapy. The remaining 16 patients had disease states of AD-Mixed (1 patient), AD-Stable (3 patients), or AD-Worse (12 patients) due to no improvement in disease or persistent progression (S2A-D, S3A-C, S4A-D, S5 and S6 Figs.). Of these 16 patients, seven patients experienced uncontrolled liver and spleen involvement (hepatomegaly and/or splenomegaly with elevated liver enzymes or serum bile acids), five patients with involvement in bones developed newly affected bone lesions (3 patients) or dilated lesions (2 patients) during chemotherapy (S7A-D, S8A, S8B Figs.), and seven patients had pituitary involvement (S9 Fig.). Some patients chose dabrafenib for more than one reason. In addition, the conditions of five patients in the RO⁺ group were complicated by HLH according to the diagnostic criteria of HLH-2004 guidelines [16].

All 20 children were initially treated with first-line chemotherapy for 0.4–13.1 months, with a median of 2.0 months. Subsequently, 12 patients received second-line chemotherapy for 1–14 courses (median of 4 courses). All patients then received dabrafenib treatment. The median duration of dabrafenib treatment was 11.4 months (range, 3.1 to 19.2 months). All patients have since completed dabrafenib monotherapy for 0.6–37.9 months. Ten patients suffered relapse or disease progression.

2. Effectiveness of dabrafenib treatment

Thirteen of the 20 patients were in the AD-Better state at the end of dabrafenib treatment (Fig. 1), with two patients in the AD-Stable state, four patients in the AD-Worse state and one patient in the AD-Mixed state. The overall ORR was 65%, and the overall DCR was 75%. The evaluation results at each observation point can be found in Table 2.

There were 14 patients in the RO⁺ group. However, no significant difference in treatment response to dabrafenib treatment was observed between RO⁺ and RO⁻ patients (78.6% vs. 33.3%, p=0.122). Notably, four of the five patients complicated by HLH experienced disease improvement, with rapid increases in temperature, hemogram and C-reactive protein (CRP) observed (Table 3). In two of these patients, the thermal spike decreased after one day of treatment, and body temperature returned to normal within 48 hours. The hemogram and CRP were restored to normal after 3 days of treatment. However, a comparable response to dabrafenib was observed between patients with and without HLH (80% vs. 60%, p=0.613), which might be due to the small sample size.

Among the four patients intolerant to chemotherapy, three patients (75%) experienced improvement, while one patient was in stable condition.

In the seven patients with poor control of the disease in the liver and spleen, five patients (71.4%) experienced improvement in all lesions except hepatic cirrhosis after dabrafenib treatment. The other two patients had only liver enlargement, elevated liver enzymes and no cirrhosis-related manifestations before the usage of dabrafenib. After dabrafenib treatment, both hepatosplenomegaly and liver damage were alleviated.

In four of five patients (80%) treated with dabrafenib due to newly affected bone lesions or dilated lesions in the bones involved during chemotherapy, the imaging findings indicated improvement in the new or dilated lesions after dabrafenib treatment.

Seven patients were treated with dabrafenib because of pituitary involvement (two patients also had progressive lesions, and one patient had an uncontrolled liver lesion), and three of them had diabetes insipidus (DI). No progression was observed by imaging. Only one of the three patients with DI had improvement of symptoms after dabrafenib treatment.

All patients survived, and 10 patients suffered from relapse or progression after dabrafenib treatment. No statistically significant difference in the event-free survival rate was observed between the RO⁺ and RO⁻ groups (χ²=0.062, p=0.804) (Fig. 2A) or between the positive mutation (at the end of targeted therapy) group and the negative mutation group (χ²=1.849, p=0.174) (Fig. 2B).

3. Relationship between dabrafenib treatment and cfBRAF^V600E

cfBRAF^V600E has become a promising indicator of treatment response and prognosis in LCH [17,18], so we next investigated the relationship between dabrafenib treatment and cfBRAF^V600E in our cohort.

Conversion to negative detection of circulating levels of cfBRAF^V600E after chemotherapy was observed in five patients. Among the other 15 patients with positive cfBRAF^V600E mutations before targeted therapy, decreased cfBRAF^V600E levels were observed at the end of targeted therapy (mean, 5.133% vs. 0.309%; t=2.429, p=0.029) (Table 1). Conversion to negative detection was achieved in nine of 15 patients (60%) after treatment with dabrafenib. The median time from dabrafenib treatment to negative detection was 3.0 months (range, 1.0 to 9.0 months). However, the association of persistent positive cfBRAF^V600E with relapse and/or treatment failure after dabrafenib treatment (83.3% vs. 35.7%, p=0.141) was not observed. This needs to be clarified in future studies with large sample sizes and long-term observations.

In addition, we did not find an association between the duration of dabrafenib treatment and positive or negative cfBRAF^V600E before targeted therapy (Z=−1.178, p=0.239).

4. Adverse effects and treatments

The most common adverse events of dabrafenib reported in the literature are skin-related toxic effects (including maculopapular rash, skin pain, and severe events, including squamous cell carcinoma and keratocanthoma), fever, fatigue, arthralgia, etc. [11].

In our cohort, 17 adverse events were observed in nine patients. Maculopapular rash was the most common (8 events, 47.1%), including grade 2/3 events in five patients and grade 1 events in three patients. Grade 2 skin pain and eye swelling with conjunctival petechia were observed in two patients, with grade 2/3 maculopapules. Six grade one adverse events were observed in eight patients, including maculopapular rash, diarrhea, blurred vision and photophobia, vomiting, ostealgia, and fever. No other adverse effects were observed in this study (Table 4).

Maculopapules faded in two of five patients after treatment with anti-allergic drugs. The anti-allergic drugs were not effective for the remaining three patients, but the rashes subsided after dabrafenib withdrawal. Skin pain in one patient was relieved by reducing the dabrafenib dosage. Eye swelling and conjunctival petechia in another patient were improved by intensive care of local lesions. Moreover, severe adverse effects of skin, such as squamous cell carcinoma and keratoacanthoma, which are common in dabrafenib treatment of melanoma patients, were not observed, suggesting the safety of dabrafenib in treating children with LCH.

Discussion

A high frequency of the BRAF^V600E mutation has been found in patients with multisystem and risk-organ-involved LCH [4,5]. Patients with the BRAF^V600E mutation are less sensitive to the standard first-line treatment, vinblastine combined with corticosteroids, and the incidence of disease recurrence and permanent sequelae are markedly more common [1,3,5]. BRAF kinase inhibitors such as dabrafenib have shown excellent effectiveness in the treatment of BRAF^V600E-positive malignancies, including melanoma, colon cancer, papillary thyroid cancers, and non-small-cell lung cancer [19–22]. Thus, it is useful to also clarify the role of dabrafenib and other BRAF kinase inhibitors in the treatment of patients with BRAF^V600E-mutated LCH.

According to the results, children with risk organs involved seem to experience benefits from targeted drugs. However, to confirm this observation, it is necessary to expand the sample size and carry out prospective research with concurrent controls. It is worth noting that patients with HLH generally have risk organ involvement and cannot tolerate strong chemotherapy. Considering the rapid recovery from symptoms and hemogram after targeted treatment, the ineffectiveness of first-line chemotherapy for most patients with concurrent HLH, and the toxic side effects of second-line chemotherapy, it may be better to use targeted drugs as the first-line treatment or for a short period followed by chemotherapy.

The results revealed satisfactory effectiveness of dabrafenib in patients who had failed to tolerate chemotherapy. In addition, improvements in liver function were obtained after the administration of dabrafenib in patients without hepatic cirrhosis, whereas cirrhosis that occurred before targeted therapy did not improve after dabrafenib treatment. Our results also showed that dabrafenib relieved DI symptoms in one patient who had developed DI for a half-year; however, no improvement was observed in two other patients who had DI for 1.5 and 2 years. Allen et al. [1] reported that three out of four patients with LCH who were treated with targeted drugs (dabrafenib or vemurafenib) for neurodegeneration (ND), a sequela of LCH due to active pathological process driven by common BRAF^V600E-positive myeloid precursors, improved in terms of clinical manifestation and imaging findings in relatively early-onset LCH-ND [23]. Thus, these results suggest that dabrafenib could have certain effects on DI (DI, like LCH-ND, is also a sequela of LCH and may be caused by persistent active pathological process as well) at the early stages of this disease, but further study is needed for confirmation.

It has been shown that half of all patients experience relapse or progression, which may be attributed to reactivation of the MAPK pathway upstream of MEK, perhaps resulting from other gene mutations in the pathway [10,24]. Due to their parents’ refusal to determine gene mutations at relapse, we cannot identify relapse-causing mutations. Relapse may also be related to low plasma concentration resulting from individual differences in pharmacokinetics or too short a duration of dabrafenib treatment. Thus, this finding highlights the significance of the role of other mutations and plasma concentrations of dabrafenib in relapse. Furthermore, the optimal therapy strategy of dabrafenib, including the time window for treatment and effective combinations with chemotherapy or other targeted drugs in children with LCH, should be explored [7,25,26].

A few patients had treatment-related adverse effects of grade 2 or above. Relief of these adverse effects was achieved after symptomatic treatment, reduction of dosage, or withdrawal. Furthermore, no severe adverse effects (squamous cell carcinoma and keratoacanthoma) were observed. Thus, dabrafenib appears to be safe to some extent for children with LCH.

Due to the limited number of patients and short-term follow-up in this study, we continue to recommend the use of dabrafenib only in patients intolerant of chemotherapy or with disease progression after chemotherapy. The main reason for dabrafenib as a second-line therapy is its unclear long-term safety in the treatment of children with LCH at present. To explore the long-term efficacy and safety of dabrafenib, a prospective study with a larger sample size is required to fully clarify the optimal dosage and duration of dabrafenib treatment.

The major limitations of this study were its retrospective nature and small sample size. A prospective study with a larger sample size and long-term observation is required.

Dabrafenib may have a beneficial effect for some children with BRAF^V600E-mutated LCH, especially high-risk patients with concomitant HLH and intolerance to chemotherapy. The adverse effects were controllable. However, further research is needed to determine the optimal dosage and duration, long-term efficacy and safety of dabrafenib.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

crt-2020-769_S1_Table.pdf

crt-2020-769_S2_Fig.pdf

crt-2020-769_S3_Fig.pdf

crt-2020-769_S4_Fig.pdf

crt-2020-769_S5_Fig.pdf

crt-2020-769_S6_Fig.pdf

crt-2020-769_S7_Fig.pdf

crt-2020-769_S8_Fig.pdf

crt-2020-769_S9_Fig.pdf

NOTES

Ethical Statement

Written informed consent was obtained from the parents or guardians of the children who served as subjects of the study. This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (IRB) of Beijing Children’s Hospital, Capital Medical University (number: 2019-k-109).

Author Contributions

Conceived and designed the analysis: Zhang R.

Collected the data: Ma HH, Zhang L, Lian HY.

Contributed data or analysis tools: Cui L, Zhang Q, Zhang LP.

Performed the analysis: Zhang R, Wang D.

Wrote the paper: Yang Y, Zhang R, Li ZG.

Revised the paper: Zhao XX, Zhao YZ, Li N, Wang TY.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Acknowledgements

This work was supported by the Capital’s Funds for Health Improvement and Research (No. 2020-2-2093 and 2020-2-1141), the Special Fund of The Pediatric Medical Coordinated Development Center of Beijing Hospitals Authority (No. XTZD20180201), the National Natural Science Foundation of China (No. 82070202), the National Science and Technology Key Projects (No. 2017ZX09304029004), Beihang University & Capital Medical University Advanced Innovation Center for Big Data-Based Precision Medicine Plan (BHME-201912), and Funding for Reform and Development of Beijing Municipal health Commission (Genetic and immunological pathogenesis of pediatric histiocytosis and its guiding role in clinical diagnosis and treatment).

Fig. 1

Improvement of bone lesions (arrows) after dabrafenib treatment. (A, C) Bone lesions in the rib and skull before dabrafenib treatment. (B, D) Improvement of bone lesions after dabrafenib treatment.

Fig. 2

Survival curves. (A) Survival analysis of the risk organ (RO)⁺ group and RO⁻ group. (B) Survival analysis of the positive mutation group or negative mutation group.

Table 1

Details of each patient’s disease characteristics

Case No.	Sex	Age at disease onset (yr)	Age started taking dabrafenib (yr)	Affected organs	Complicated with HLH	Disease state before dabrafenib treatment	Disease state level at the end of dabrafenib treatment	cfBRAF^V600E level before dabrafenib treatment	cfBRAF^V600E level at the end of dabrafenib treatment	Duration of dabrafenib treatment (mo)
1	M	1.7	2.9	Skin, bones, lung, liver, ear, lymph nodes	N	AD-Worse	AD-Better	+ (5.00%)	-	3.9
2	M	0.1	2.1	Skin, bones, lung, liver, spleen, ear lymph nodes, thymus	N	AD-Stable	AD-Better	+ (5.00%)	+ (1.73%)	17.7
3	F	1.4	2.3	Skin, bones, lung, liver, spleen, hematopoietic system, lymph nodes	Y	AD-Stable	AD-Better	-	-	3.7
4	M	1.2	3.1	Liver, spleen, ear, pituitary, thyroid	N	AD-Worse	AD-Better	+ (6.31%)	-	6.1
5	F	0.3	0.8	Skin, bones, lung, liver, spleen, hematopoietic system, ear, lymph nodes	Y	AD-Worse	AD-Better	+ (2.80%)	+ (0.51%)	19.2
6	M	1.0	2.1	Skin, bones, liver, spleen, ear	N	AD-Worse	AD-Better	+ (0.20%)	-	6.4
7	M	3.2	4.3	Bones, liver, pituitary, thyroid, biliary tract	N	AD-Worse	AD-Mixed	+ (0.75%)	-	7.0
8	M	1.0	2.4	Bones, pituitary, oral cavity	N	AD-Stable	AD-Better	-	-	9.8
9	M	5.1	6.5	Bones, pituitary	N	AD-Stable	AD-Stable	-	-	12.1
10	M	1.1	2.7	Skin, bones, lung, liver, ear	N	AD-Worse	AD-Better	-	-	13.0
11	F	0.1	0.8	Skin, bones, lung, liver, spleen, hematopoietic system, lymph nodes, thymus	N	AD-Worse	AD-Better	+ (24.05%)	-	18.4
12	M	2.0	2.6	Bones, liver, spleen, ear	N	AD-Worse	AD-Better	+ (0.51%)	-	11.7
13	M	2.5	3.5	Skin, bones, ear, pituitary	N	AD-Worse	AD-Stable	+ (0.27%)	-	11.1
14	F	1.0	3.3	Skin, bones, lung, ear, pituitary	N	AD-Worse	AD-Worse	-	-	4.4
15	M	0.8	0.9	Skin, bones, ear pituitary	N	AD-Worse	AD-Better	+ (3.28%)	+ (0.24%)	14.0
16	M	0.2	0.6	Skin, liver, spleen, hematopoietic system	Y	AD-Worse	AD-Better	+ (3.29%)	+ (1.13%)	16.5
17	F	0.2	0.8	Skin, bones, lung, liver, spleen, hematopoietic system, lymph nodes	Y	AD-Worse	AD-Better	+ (22.52%)	+ (0.13%)	13.8
18	M	0.9	1.1	Skin, lung, liver, hematopoietic system, ear, biliary tract, thyroid	Y	AD-Stable	AD-Worse	+ (1.80%)	+ (0.89%)	10.0
19	M	0.3	1.2	Skin, bones, lung, liver	N	AD-Mixed	AD-Worse	+ (0.18%)	-	18.3
20	F	1.6	2.6	Bones, thyroid	N	AD-Worse	AD-Worse	+ (1.03%)	-	3.1

AD, active disease; F, female; HLH, hemophagocytic lymphohistiocytosis; M, male; N, no; Y, yes.

Table 2

Details of the evaluation results at each observation point

Observation points	AD-Better	AD-Stable	AD-Mixed	AD-Worse	Drug withdrawal
Month 1	15	2	3	0	0
Month 3	13	2	2	3	0
Month 6	13	2	1	1	3
Month 9	7	1	2	2	8
Month 12	6	1	1	1	11

AD, active disease.

Table 3

Details of five patients complicated by HLHa)

	Case 3	Case 5	Case 16	Case 17	Case 18
Before dabrafenib
Temperature (°C)	Normal	Normal	38.6	Normal	39
CRP (mg/L)	24	57	57	62	45
Hemoglobin (g/L)	105	72	74	87	80
Platelet (×10⁹/L)	68	271	28	165	172
Neutrophil (×10⁹/L)	1.37	5.38	0.84	1.84	0.61
Splenomegaly (below the left costal margin) (cm)	4.0	6.5	5.7	3.0	1.3
Triglyceride (mmol/L)	2.04	4.04	6.57	6.88	5.18
Fibrinogen (g/L)	2.90	0.87	1	1.45	1.16
Hemophagocytosis	+	+	+	+	–
NK-cell activity (%)	13.62	17.01	NA	14.49	11.46
Ferritin (μg/L)	NA	NA	124.2	135.2	98.8
sCD25 (U/mL)	NA	NA	20,725	22,803	14,242
Three days after starting dabrafenib
Temperature (°C)	Normal	Normal	Normal	Normal	Normal
CRP (mg/L)	< 5	< 5	< 5	8	< 5
Hemoglobin (g/L)	127	112	96	92	91
Platelet (×10⁹/L)	180	302	100	347	409
Neutrophil (×10⁹/L)	2.40	1.87	0.38	2.24	1.80
Splenomegaly (below the left costal margin)	NA	NA	NA	NA	NA
Triglyceride (mmol/L)	1.33	NA	4.42	3.85	NA
Fibrinogen (g/L)	NA	0.87	1.01	NA	NA
Hemophagocytosis	NA	NA	NA	NA	NA
NK-cell activity (%)	NA	NA	NA	NA	NA
Ferritin (μg/L)	NA	548.9	NA	132.5	NA
sCD25 (U/ml)	NA	NA	NA	NA	NA
One month after starting Dabrafenib
Temperature (°C)	Normal	Normal	Normal	Normal	Normal
CRP (mg/L)	NA	NA	NA	NA	NA
Hemoglobin (g/L)	127	131	118	118	115
Platelet (10⁹/L)	180	283	370	530	567
Neutrophil (10⁹/L)	2.40	5.37	3.49	3.12	5.44
Splenomegaly (below the left costal margin) (cm)	3.8	2.3	No splenomegaly	No splenomegaly	No splenomegaly
Triglyceride (mmol/L)	0.7	0.9	1	0.8	2.73
Fibrinogen (g/L)	11.9	NA	NA	3.2	2.36
Hemophagocytosis	NA	NA	NA	NA	NA
NK-cell activity (%)	14.83	NA	NA	NA	NA
Ferritin (μg/L)	NA	521.2	NA	NA	NA
sCD25 (U/mL)	NA	NA	NA	NA	NA

CRP, C-reactive protein; HLH, hemophagocytic lymphohistiocytosis; NA, not available; NK-cell, natural killer cell; sCD25, soluble CD25.

^a) The diagnosis of HLH can be established if one of either 1 or 2 below is fulfilled: (1) a molecular diagnosis consistent with HLH, (2) diagnostic criteria for HLH fulfilled (five out of the eight criteria below): (a) fever, (b) splenomegaly, (c) cytopenias (affecting ≥ 2 of 3 lineages in the peripheral blood): hemoglobin < 90 g/L (in infants < 4 weeks: hemoglobin < 100 g/L), platelets < 100×10⁹/L, neutrophils < 1.0×10⁹/L, (d) ferritin ≥ 500 μg/L, (e) hypertriglyceridemia and/or hypofibrinogenemia: fasting triglycerides ≥ 3.0 mmol/L, fibrinogen ≤ 1.5 g/L, (f) hemophagocytosis in bone marrow or spleen or lymph nodes, (g) soluble CD25 (i.e., soluble IL-2 receptor) ≥ 2,400 U/mL, (h) NK-cell activity < 15.11% (according to our laboratory reference).

Table 4

Different grades of treatment-related adverse events

Adverse events	Grade	No. of casesa)	Adverse events occurred after starting targeted treatment (wk)
Maculopapule	1	3	1–16
	2	4	0–2
	3	1	1
Diarrhea	1	2	4
Skin pain	2	1	1
Eye swelling and conjunctival petechia	2	1	4
Blurred vision and photophobia	1	1	4
Vomiting	1	1	5
Ostealgia	1	1	12
Fever	1	2	0–1

^a) Some patients had more than one adverse event.

REFERENCES

1. Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018;379:856–68. Article PubMed PMC
2. Tran G, Huynh TN, Paller AS. Langerhans cell histiocytosis: a neoplastic disorder driven by Ras-ERK pathway mutations. J Am Acad Dermatol. 2018;78:579–90. Article PubMed
3. Heritier S, Jehanne M, Leverger G, Emile JF, Alvarez JC, Haroche J, et al. Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis. JAMA Oncol. 2015;1:836–8. Article PubMed
4. Heritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol. 2016;34:3023–30. Article PubMed PMC
5. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919–23. Article PubMed PMC
6. Abla O, Weitzman S. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition. Hematology Am Soc Hematol Educ Program. 2015;2015:565–70. Article PubMed
7. Cebollero A, Puertolas T, Pajares I, Calera L, Anton A. Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma. Mol Clin Oncol. 2016;5:458–62. Article PubMed PMC
8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16. Article PubMed PMC
9. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65. Article PubMed
10. Hertzman Johansson C, Egyhazi Brage S. BRAF inhibitors in cancer therapy. Pharmacol Ther. 2014;142:176–82. Article PubMed
11. Kieran MW, Geoerger B, Dunkel IJ, Broniscer A, Hargrave D, Hingorani P, et al. A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation-positive solid tumors. Clin Cancer Res. 2019;25:7294–302. Article PubMed
12. Toll SA, Tran HN, Cotter J, Judkins AR, Tamrazi B, Biegel JA, et al. Sustained response of three pediatric BRAF(V600E) mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy. Oncotarget. 2019;10:551–7. Article PubMed PMC
13. Wang D, Cui L, Li ZG, Zhang L, Lian HY, Ma HH, et al. Clinical research of pulmonary Langerhans cell histiocytosis in children. Chin Med J (Engl). 2018;131:1793–8. Article PubMed PMC
14. LCH evaluation and treatment guidelines [Internet]. Pitman NJ: Histiocyte Society; 2009. [cited 2020 Sep 14]. Available from: https://histiocytesociety.org/document.doc?id=290
15. Common Terminology Criteria for Adverse Events (CTCAE) [Internet]. Bethesda, MD: National Cancer Institute; 2017. [cited 2020 Sep 14]. Available from: https://ctep.cancer.gov/
16. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31. Article PubMed
17. Ozer E, Sevinc A, Ince D, Yuzuguldu R, Olgun N. BRAF V600E mutation: a significant biomarker for prediction of disease relapse in pediatric Langerhans cell histiocytosis. Pediatr Dev Pathol. 2019;22:449–55. Article PubMed
18. Heritier S, Helias-Rodzewicz Z, Lapillonne H, Terrones N, Garrigou S, Normand C, et al. Circulating cell-free BRAF(V600E) as a biomarker in children with Langerhans cell histiocytosis. Br J Haematol. 2017;178:457–67. Article PubMed
19. Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, et al. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E) or BRAF(V600K) mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:701–10. Article PubMed
20. Awada G, Seremet T, Fostier K, Everaert H, Neyns B. Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition. Blood Adv. 2018;2:2156–8. Article PubMed PMC
21. Mourah S, Lorillon G, Meignin V, Vercellino L, de Margerie-Mellon C, Pages C, et al. Dramatic transient improvement of metastatic BRAF(V600E)-mutated Langerhans cell sarcoma under treatment with dabrafenib. Blood. 2015;126:2649–52. Article PubMed PDF
22. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726–36. Article PubMed PMC
23. McClain KL, Picarsic J, Chakraborty R, Zinn D, Lin H, Abhyankar H, et al. CNS Langerhans cell histiocytosis: common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018;124:2607–20. Article PubMed PMC
24. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9. Article PubMed
25. Yamazaki N, Tsutsumida A, Takahashi A, Namikawa K, Yoshikawa S, Fujiwara Y, et al. Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma. J Dermatol. 2018;45:397–407. Article PubMed PMC
26. Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18:863–73. Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Targeted therapy and immunotherapy for orbital and periorbital tumors: a major review
Emmanuel Lee Boniao, Richard C. Allen, Gangadhara Sundar
Orbit.2024; 43(5): 656. CrossRef
Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone
Wenqian Wang, Jian Ge, Honghao Ma, Hongyun Lian, Lei Cui, Yunze Zhao, Zhigang Li, Tianyou Wang, Rui Zhang
BMC Pediatrics.2024;[Epub] CrossRef
Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study
Jiaying Lei, Wenxia Wang, Danna Lin, Chengguang Zhu, Wenguang Jia, Wenjun Weng, Xiaoshan Liu, Yuhan Ma, Zhixuan Wang, Lihua Yang, Xiangling He, Yunyan He, Yang LI
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Clinical features and treatment outcomes of liver involvement in paediatric Langerhans cell histiocytosis
Xinshun Ge, Wenxin Ou, Ang Wei, Hongyun Lian, Honghao Ma, Lei Cui, Dong Wang, Liping Zhang, Xiaoman Wang, Lejian He, Rui Zhang, Tianyou Wang
BMC Pediatrics.2024;[Epub] CrossRef
Refractory juvenile xanthogranuloma of the mastoid bone responsive to trametinib
Isaac Hauk, Ignacio Gonzalez‐Gomes, Deepak Chellapandian, Jonathan Metts, Peter H. Shaw
Pediatric Blood & Cancer.2024;[Epub] CrossRef
Advancements in the understanding and management of histiocytic neoplasms
Kyung-Nam Koh, Su Hyun Yoon, Sung Han Kang, Hyery Kim, Ho Joon Im
Blood Research.2024;[Epub] CrossRef
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
Paul G. Kemps, F. J. Sherida H. Woei-A-Jin, Patrick Schöffski, Thomas Tousseyn, Isabelle Vanden Bempt, Friederike A. G. Meyer-Wentrup, Natasja Dors, Natasha K. A. van Eijkelenburg, Marijn A. Scheijde-Vermeulen, Ingrid M. Jazet, Maarten Limper, Margot Jak,
Blood Neoplasia.2024; 1(3): 100023. CrossRef
The clinical impact of serum soluble CD25 levels in children with Langerhans cell histiocytosis
Zi-Jing Zhao, Hong-Yun Lian, Wei-Jing Li, Qing Zhang, Hong-Hao Ma, Dong Wang, Yun-Ze Zhao, Ting Zhu, Hua-Lin Li, Xiao-Tong Huang, Tian-You Wang, Rui Zhang, Lei Cui, Zhi-Gang Li
Jornal de Pediatria.2024;[Epub] CrossRef
Liver transplantation in a child with sclerosing cholangitis due to Langerhans cell histiocytosis: a case report
Xue-Lian Wang, Chun-Xiao Fang, Min-Xia Chen, Hua-Mei Yang, Lan-Hui She, Yu Gong, Yi Xu, Wei-Qiang Xiao, Jin-Sheng Tian, Bin Ai, Li Huang, Xu-Fang Li
Frontiers in Pediatrics.2024;[Epub] CrossRef
BRAF V600E gene mutation is present in primary intraosseous Rosai-Dorfman disease
Lokman Cevik, Swati Satturwar, Dan Jones, Joel Mayerson, Steve Oghumu, O. Hans Iwenofu
Human Pathology.2024; : 105702. CrossRef
Langerhans cell histiocytosis as a clonal disease of mononuclear phagocyte system
Evgeniy F. Khynku, Maria K. Monaenkova, Olga B. Tamrazova, Alexey V. Taganov, Мarina А. Gureeva, Gayane E. Bagramova, Anton V. Molochkov
Almanac of Clinical Medicine.2023; 50(7): 428. CrossRef
Lineage switching of the cellular distribution of BRAF V600E in multisystem Langerhans cell histiocytosis
Paul Milne, Simon Bomken, Olga Slater, Ashish Kumar, Adam Nelson, Somak Roy, Jessica Velazquez, Kshitij Mankad, James Nicholson, Dan Yeomanson, Richard Grundy, Ahmed Kamal, Anthony Penn, Jane Pears, Gerard Millen, Bruce Morland, James Hayden, Jason Lam, M
Blood Advances.2023; 7(10): 2171. CrossRef
Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors
Ashley V. Geerlinks, Oussama Abla
Pediatric Drugs.2023; 25(4): 399. CrossRef
Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
James A. Whitlock, Birgit Geoerger, Ira J. Dunkel, Michael Roughton, Jeea Choi, Lisa Osterloh, Mark Russo, Darren Hargrave
Blood Advances.2023; 7(15): 3806. CrossRef
Therapiestrategien bei Kindern und Jugendlichen mit Langerhanszell Histiozytosen
Anke Elisabeth Barnbrock, Caroline Hutter, Konrad Bochennek, Milen Minkov, Thomas Lehrnbecher
Klinische Pädiatrie.2023; 235(06): 342. CrossRef
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms
Benjamin H. Durham, Oshrat Hershkovitz-Rokah, Omar Abdel-Wahab, Mariko Yabe, Young Rock Chung, Gilad Itchaki, Maayan Ben-Sasson, Vered A. Asher-Guz, David Groshar, Seyram A. Doe-Tetteh, Tina Alano, David B. Solit, Ofer Shpilberg, Eli L. Diamond, Roei D. M
Blood Advances.2023; 7(23): 7319. CrossRef
Validation of Liquid Chromatography Coupled with Tandem Mass Spectrometry for the Determination of 12 Tyrosine Kinase Inhibitors (TKIs) and Their Application to Therapeutic Drug Monitoring in Adult and Pediatric Populations
Marie Bellouard, Jean Donadieu, Pauline Thiebot, Etienne Giroux Leprieur, Philippe Saiag, Isabelle Etting, Pamela Dugues, Emuri Abe, Jean-Claude Alvarez, Islam-Amine Larabi
Pharmaceutics.2023; 16(1): 5. CrossRef
Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease
Oussama Abla
Hematology.2023; 2023(1): 386. CrossRef
Characteristics and Treatment Outcomes of Pediatric Langerhans Cell Histiocytosis with Thymic Involvement
Ja-Feng Yao, Dong Wang, Hong-Hao Ma, Hong-Yun Lian, Li Zhang, Tian-You Wang, Zhi-Gang Li, Jin Jiang, Lei Cui, Rui Zhang
The Journal of Pediatrics.2022; 244: 194. CrossRef
Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis
Dong Wang, Xi-Hua Chen, Ang Wei, Chun-Ju Zhou, Xue Zhang, Hong-Hao Ma, Hong-Yun Lian, Li Zhang, Qing Zhang, Xiao-Tong Huang, Chan-Juan Wang, Ying Yang, Wei Liu, Tian-You Wang, Zhi-Gang Li, Lei Cui, Rui Zhang
Orphanet Journal of Rare Diseases.2022;[Epub] CrossRef
Current perspectives on the role of liver transplantation for Langerhans cell histiocytosis: A narrative review
Jagadeesh Menon, Ashwin Rammohan, Mukul Vij, Naresh Shanmugam, Mohamed Rela
World Journal of Gastroenterology.2022; 28(30): 4044. CrossRef
Research Progress of BRAF V600E Gene Mutation in Papillary Thyroid Carcinoma
延泽刘
Advances in Clinical Medicine.2022; 12(09): 8499. CrossRef
Recent advances in the understanding of the molecular pathogenesis and targeted therapy options in Langerhans cell histiocytosis
Jin Kyung Suh, Sunghan Kang, Hyery Kim, Ho Joon Im, Kyung-Nam Koh
BLOOD RESEARCH.2021; 56(S1): S65. CrossRef
Improvement in Pituitary Imaging After Targeted Therapy in Three Children with BRAF-Mutated Langerhans Cell Histiocytosis with Pituitary Involvement

Ying Yang, Dong Wang, Na Li, Honghao Ma, Hongyun Lian, Lei Cui, Qing Zhang, Xiaoxi Zhao, Liping Zhang, Yunze Zhao, Chanjuan Wang, Li Zhang, Tianyou Wang, Zhigang Li, Rui Zhang
OncoTargets and Therapy.2020; Volume 13: 12357. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAF^V600E-Mutated Langerhans Cell Histiocytosis

Cancer Res Treat. 2021;53(1):261-269. Published online September 15, 2020

DOI: https://doi.org/10.4143/crt.2020.769

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAF^V600E-Mutated Thyroid Cancer

Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAF^V600E-Mutated Langerhans Cell Histiocytosis

Fig. 1 Improvement of bone lesions (arrows) after dabrafenib treatment. (A, C) Bone lesions in the rib and skull before dabrafenib treatment. (B, D) Improvement of bone lesions after dabrafenib treatment.

Fig. 2 Survival curves. (A) Survival analysis of the risk organ (RO)+ group and RO− group. (B) Survival analysis of the positive mutation group or negative mutation group.

Fig. 1

Fig. 2

Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAF^V600E-Mutated Langerhans Cell Histiocytosis

Table 1

Details of each patient’s disease characteristics

Case No.	Sex	Age at disease onset (yr)	Age started taking dabrafenib (yr)	Affected organs	Complicated with HLH	Disease state before dabrafenib treatment	Disease state level at the end of dabrafenib treatment	cfBRAF^V600E level before dabrafenib treatment	cfBRAF^V600E level at the end of dabrafenib treatment	Duration of dabrafenib treatment (mo)
1	M	1.7	2.9	Skin, bones, lung, liver, ear, lymph nodes	N	AD-Worse	AD-Better	+ (5.00%)	-	3.9
2	M	0.1	2.1	Skin, bones, lung, liver, spleen, ear lymph nodes, thymus	N	AD-Stable	AD-Better	+ (5.00%)	+ (1.73%)	17.7
3	F	1.4	2.3	Skin, bones, lung, liver, spleen, hematopoietic system, lymph nodes	Y	AD-Stable	AD-Better	-	-	3.7
4	M	1.2	3.1	Liver, spleen, ear, pituitary, thyroid	N	AD-Worse	AD-Better	+ (6.31%)	-	6.1
5	F	0.3	0.8	Skin, bones, lung, liver, spleen, hematopoietic system, ear, lymph nodes	Y	AD-Worse	AD-Better	+ (2.80%)	+ (0.51%)	19.2
6	M	1.0	2.1	Skin, bones, liver, spleen, ear	N	AD-Worse	AD-Better	+ (0.20%)	-	6.4
7	M	3.2	4.3	Bones, liver, pituitary, thyroid, biliary tract	N	AD-Worse	AD-Mixed	+ (0.75%)	-	7.0
8	M	1.0	2.4	Bones, pituitary, oral cavity	N	AD-Stable	AD-Better	-	-	9.8
9	M	5.1	6.5	Bones, pituitary	N	AD-Stable	AD-Stable	-	-	12.1
10	M	1.1	2.7	Skin, bones, lung, liver, ear	N	AD-Worse	AD-Better	-	-	13.0
11	F	0.1	0.8	Skin, bones, lung, liver, spleen, hematopoietic system, lymph nodes, thymus	N	AD-Worse	AD-Better	+ (24.05%)	-	18.4
12	M	2.0	2.6	Bones, liver, spleen, ear	N	AD-Worse	AD-Better	+ (0.51%)	-	11.7
13	M	2.5	3.5	Skin, bones, ear, pituitary	N	AD-Worse	AD-Stable	+ (0.27%)	-	11.1
14	F	1.0	3.3	Skin, bones, lung, ear, pituitary	N	AD-Worse	AD-Worse	-	-	4.4
15	M	0.8	0.9	Skin, bones, ear pituitary	N	AD-Worse	AD-Better	+ (3.28%)	+ (0.24%)	14.0
16	M	0.2	0.6	Skin, liver, spleen, hematopoietic system	Y	AD-Worse	AD-Better	+ (3.29%)	+ (1.13%)	16.5
17	F	0.2	0.8	Skin, bones, lung, liver, spleen, hematopoietic system, lymph nodes	Y	AD-Worse	AD-Better	+ (22.52%)	+ (0.13%)	13.8
18	M	0.9	1.1	Skin, lung, liver, hematopoietic system, ear, biliary tract, thyroid	Y	AD-Stable	AD-Worse	+ (1.80%)	+ (0.89%)	10.0
19	M	0.3	1.2	Skin, bones, lung, liver	N	AD-Mixed	AD-Worse	+ (0.18%)	-	18.3
20	F	1.6	2.6	Bones, thyroid	N	AD-Worse	AD-Worse	+ (1.03%)	-	3.1

AD, active disease; F, female; HLH, hemophagocytic lymphohistiocytosis; M, male; N, no; Y, yes.

Table 2

Details of the evaluation results at each observation point

Observation points	AD-Better	AD-Stable	AD-Mixed	AD-Worse	Drug withdrawal
Month 1	15	2	3	0	0
Month 3	13	2	2	3	0
Month 6	13	2	1	1	3
Month 9	7	1	2	2	8
Month 12	6	1	1	1	11

AD, active disease.

Table 3

Details of five patients complicated by HLHa)

	Case 3	Case 5	Case 16	Case 17	Case 18
Before dabrafenib
Temperature (°C)	Normal	Normal	38.6	Normal	39
CRP (mg/L)	24	57	57	62	45
Hemoglobin (g/L)	105	72	74	87	80
Platelet (×10⁹/L)	68	271	28	165	172
Neutrophil (×10⁹/L)	1.37	5.38	0.84	1.84	0.61
Splenomegaly (below the left costal margin) (cm)	4.0	6.5	5.7	3.0	1.3
Triglyceride (mmol/L)	2.04	4.04	6.57	6.88	5.18
Fibrinogen (g/L)	2.90	0.87	1	1.45	1.16
Hemophagocytosis	+	+	+	+	–
NK-cell activity (%)	13.62	17.01	NA	14.49	11.46
Ferritin (μg/L)	NA	NA	124.2	135.2	98.8
sCD25 (U/mL)	NA	NA	20,725	22,803	14,242
Three days after starting dabrafenib
Temperature (°C)	Normal	Normal	Normal	Normal	Normal
CRP (mg/L)	< 5	< 5	< 5	8	< 5
Hemoglobin (g/L)	127	112	96	92	91
Platelet (×10⁹/L)	180	302	100	347	409
Neutrophil (×10⁹/L)	2.40	1.87	0.38	2.24	1.80
Splenomegaly (below the left costal margin)	NA	NA	NA	NA	NA
Triglyceride (mmol/L)	1.33	NA	4.42	3.85	NA
Fibrinogen (g/L)	NA	0.87	1.01	NA	NA
Hemophagocytosis	NA	NA	NA	NA	NA
NK-cell activity (%)	NA	NA	NA	NA	NA
Ferritin (μg/L)	NA	548.9	NA	132.5	NA
sCD25 (U/ml)	NA	NA	NA	NA	NA
One month after starting Dabrafenib
Temperature (°C)	Normal	Normal	Normal	Normal	Normal
CRP (mg/L)	NA	NA	NA	NA	NA
Hemoglobin (g/L)	127	131	118	118	115
Platelet (10⁹/L)	180	283	370	530	567
Neutrophil (10⁹/L)	2.40	5.37	3.49	3.12	5.44
Splenomegaly (below the left costal margin) (cm)	3.8	2.3	No splenomegaly	No splenomegaly	No splenomegaly
Triglyceride (mmol/L)	0.7	0.9	1	0.8	2.73
Fibrinogen (g/L)	11.9	NA	NA	3.2	2.36
Hemophagocytosis	NA	NA	NA	NA	NA
NK-cell activity (%)	14.83	NA	NA	NA	NA
Ferritin (μg/L)	NA	521.2	NA	NA	NA
sCD25 (U/mL)	NA	NA	NA	NA	NA

CRP, C-reactive protein; HLH, hemophagocytic lymphohistiocytosis; NA, not available; NK-cell, natural killer cell; sCD25, soluble CD25.

^a)The diagnosis of HLH can be established if one of either 1 or 2 below is fulfilled: (1) a molecular diagnosis consistent with HLH, (2) diagnostic criteria for HLH fulfilled (five out of the eight criteria below): (a) fever, (b) splenomegaly, (c) cytopenias (affecting ≥ 2 of 3 lineages in the peripheral blood): hemoglobin < 90 g/L (in infants < 4 weeks: hemoglobin < 100 g/L), platelets < 100×10⁹/L, neutrophils < 1.0×10⁹/L, (d) ferritin ≥ 500 μg/L, (e) hypertriglyceridemia and/or hypofibrinogenemia: fasting triglycerides ≥ 3.0 mmol/L, fibrinogen ≤ 1.5 g/L, (f) hemophagocytosis in bone marrow or spleen or lymph nodes, (g) soluble CD25 (i.e., soluble IL-2 receptor) ≥ 2,400 U/mL, (h) NK-cell activity < 15.11% (according to our laboratory reference).

Table 4

Different grades of treatment-related adverse events

Adverse events	Grade	No. of casesa)	Adverse events occurred after starting targeted treatment (wk)
Maculopapule	1	3	1–16
	2	4	0–2
	3	1	1
Diarrhea	1	2	4
Skin pain	2	1	1
Eye swelling and conjunctival petechia	2	1	4
Blurred vision and photophobia	1	1	4
Vomiting	1	1	5
Ostealgia	1	1	12
Fever	1	2	0–1

^a)Some patients had more than one adverse event.

Table 1 Details of each patient’s disease characteristics

AD, active disease; F, female; HLH, hemophagocytic lymphohistiocytosis; M, male; N, no; Y, yes.

Table 2 Details of the evaluation results at each observation point

AD, active disease.

Table 3 Details of five patients complicated by HLHa)

CRP, C-reactive protein; HLH, hemophagocytic lymphohistiocytosis; NA, not available; NK-cell, natural killer cell; sCD25, soluble CD25.

The diagnosis of HLH can be established if one of either 1 or 2 below is fulfilled: (1) a molecular diagnosis consistent with HLH, (2) diagnostic criteria for HLH fulfilled (five out of the eight criteria below): (a) fever, (b) splenomegaly, (c) cytopenias (affecting ≥ 2 of 3 lineages in the peripheral blood): hemoglobin < 90 g/L (in infants < 4 weeks: hemoglobin < 100 g/L), platelets < 100×10⁹/L, neutrophils < 1.0×10⁹/L, (d) ferritin ≥ 500 μg/L, (e) hypertriglyceridemia and/or hypofibrinogenemia: fasting triglycerides ≥ 3.0 mmol/L, fibrinogen ≤ 1.5 g/L, (f) hemophagocytosis in bone marrow or spleen or lymph nodes, (g) soluble CD25 (i.e., soluble IL-2 receptor) ≥ 2,400 U/mL, (h) NK-cell activity < 15.11% (according to our laboratory reference).